Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad Tang

Showing results (201-210 of 221) with videos related to

Pageof 23
Sort By:
International Journal of Radiation Oncology, Biology, Physics|November 1, 2024
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 TrialJay P Reddy, Alexander D Sherry, Bryan Fellman, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
The Lancet. Oncology|October 30, 2016
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R Gomez, George R Blumenschein, J Jack Lee, et al.
The Lancet. Oncology|February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaborationChad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
JAMA Oncology|April 6, 2023
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical TrialChad Tang, Alexander D Sherry, Cara Haymaker, et al.
Journal for Immunotherapy of Cancer|July 4, 2023
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trialMehmet Altan, Yan Wang, Juhee Song, et al.
Clinical and Translational Radiation Oncology|August 27, 2024
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer centerAlan J Sosa, Michael K Rooney, Howard D Thames, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2026
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Solid Tumors: Primary Analysis of All Tumor-Histology Baskets of the Phase II Randomized EXTEND TrialAlexander D Sherry, Cara Haymaker, Shuqi Wang, et al.
The Lancet. Oncology|September 7, 2025
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trialChad Tang, Alexander D Sherry, Aaron Seo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 2024
Knowledge-based planning for fully automated radiation therapy treatment planning of 10 different cancer sitesChristine V Chung, Meena S Khan, Adenike Olanrewaju, et al.
Pageof 23

Showing results (201-210 of 221) with videos related to

Sort By:
Pageof 23
International Journal of Radiation Oncology, Biology, Physics|November 1, 2024
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 TrialJay P Reddy, Alexander D Sherry, Bryan Fellman, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
The Lancet. Oncology|October 30, 2016
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R Gomez, George R Blumenschein, J Jack Lee, et al.
The Lancet. Oncology|February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaborationChad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
JAMA Oncology|April 6, 2023
Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical TrialChad Tang, Alexander D Sherry, Cara Haymaker, et al.
Journal for Immunotherapy of Cancer|July 4, 2023
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trialMehmet Altan, Yan Wang, Juhee Song, et al.
Clinical and Translational Radiation Oncology|August 27, 2024
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer centerAlan J Sosa, Michael K Rooney, Howard D Thames, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2026
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Solid Tumors: Primary Analysis of All Tumor-Histology Baskets of the Phase II Randomized EXTEND TrialAlexander D Sherry, Cara Haymaker, Shuqi Wang, et al.
The Lancet. Oncology|September 7, 2025
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trialChad Tang, Alexander D Sherry, Aaron Seo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 2024
Knowledge-based planning for fully automated radiation therapy treatment planning of 10 different cancer sitesChristine V Chung, Meena S Khan, Adenike Olanrewaju, et al.
Pageof 23